Followers | 130 |
Posts | 7536 |
Boards Moderated | 1 |
Alias Born | 02/25/2014 |
Friday, March 13, 2020 10:46:51 AM
Celgene Corp trading at $108
Revenue: $15.28 billion USD (2018)
Sumitomo Pharmaceuticals
https://www.ds-pharma.com/ir/
Trading Japan at 1358 yen or $ 13
Revenue 357.0 billion yen in 2019 or $ 3,440,409,000
Nobelpharma Co
https://www.nobelpharma.co.jp/en/
Paul subsequently founded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., which is now one of Japan’s most profitable orphan drug companies. As President of the U.S. division and a co-Founder,he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.
Teva Pharmaceuticals
https://www.tevapharm.com/
Teva stock price $9.01
ICOS
Icos Corporation (trademark ICOS) was an American biotechnology company and the largest biotechnology company in the U.S. state of Washington, before it was sold to Eli Lilly and Company in 2007.
Neurocrine
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome.[9] The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
NBIX trading at $85.90
Gilead
GILD trading $73
Gilead Sciences' Remdesivir Is Being Used to Treat Coronavirus Patients
Now let's see what is PAUL M. MICHAELS doing?
https://sunmedadvisors.com/
Current projects:
- Small molecule drug that penetrates the blood-brain barrier and activates PKC enzymes, resulting in improved synaptic function, new synapse formation, repair of damaged synapses, and prevention of neuronal death in Alzheimer’s.
Neurology Phase 2 Product
Novel first-in-class drug with ground-breaking potential utilizing a unique delivery method to slow or stop the progression of Glaucoma and dry AMD - neurodegenerative diseases and leading causes of blindness
- Reformulation of steroid for delayed release in the intestinal tract thus reducing prototypical side effect profile of orally administered steriods
- Immuno resistant device holding stem cells, allowing them to produce insulin without triggering the body's T-Cell response
- Reformulation of topical into oral formulation for various blood cancers
- Licensed device from University that creates Apoptosis in patients reducing inflammation in major organs and blood vessels
- Novel first-in-class drug with ground-breaking potential utilizing a unique delivery method to slow or stop the progression of Glaucoma and dry AMD - neurodegenerative diseases and leading causes of blindness
-Low cost universal insulin delivery system licensed form large pharma for initial 510K approval expected within 12 months
- Reformulation of topical into oral formulation for various blood cancers
Check here for merger updates https://www.connectyx.com/
Stay tuned!
Recent CUBT News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/06/2024 09:31:41 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM